{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-127231","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.321039+00:00","generated_at":"2026-05-29T05:07:05.630127+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SELLAS triggers interim analysis in Phase 3 REGAL trial of GPS in AML; IDMC meeting in Jan 2025","bullets":["Pre-specified threshold of 60 deaths reached, triggering IDMC interim analysis.","IDMC to review efficacy, futility, and safety data from the Phase 3 REGAL trial in January 2025.","GPS is a potential new treatment for acute myeloid leukemia (AML).","Company hosted a webcast on December 10, 2024, to discuss the milestone and possible outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-127231","json":"https://secwatch.observer/filing/0001104659-24-127231.json","markdown":"https://secwatch.observer/filing/0001104659-24-127231.md","text":"https://secwatch.observer/filing/0001104659-24-127231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924127231/0001104659-24-127231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924127231/tm2430677d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:07:05.630127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}